Xigen Overview
- Founded
-
2002
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
Xigen General Information
Description
Developer of innovative therapeutic peptides intended to use it against inflammation. The company's peptides have metabolic stability, specificity and are selectively delivered to intracellular targets through proprietary carrier molecules, enabling physicians to treat a broad range of diseases.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Route de la corniche 4
- 1066 Epalinges
- Switzerland
Xigen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Feb-2021 | 000.00 | Completed | Out of Business | ||
| 4. Later Stage VC (Series B) | 16-Nov-2009 | 0000 | 000.00 | Completed | Generating Revenue | |
| 3. Secondary Transaction - Private | 01-Jan-2008 | 000.00 | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series A) | 06-Sep-2005 | $20.7M | $20.7M | Completed | Generating Revenue | |
| 1. Angel (individual) | 19-Jan-2004 | Completed | Generating Revenue |
Xigen Patents
Xigen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2009253347-B2 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases | Inactive | 30-May-2008 | 000000000 | |
| AU-2009253347-A1 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases | Active | 30-May-2008 | 000000000 | |
| CA-2725547-A1 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases | Inactive | 30-May-2008 | 000000000 | |
| EP-2489362-A1 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases | Inactive | 30-May-2008 | 000000000 | 00 |
| EP-2224941-A1 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases | Active | 30-May-2008 | A61K38/16 |
Xigen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
